Close Menu
    What's Hot

    Democrats Trump Investigations Plans Gain Momentum

    November 16, 2026 2:37 pm

    Glenn Close Honorary Oscar Marks Career Milestone

    November 16, 2026 2:33 pm

    San Francisco 49ers Cowboys Victory Stuns Dallas

    November 16, 2026 2:32 pm
    Facebook X (Twitter) Instagram
    Trending
    • Democrats Trump Investigations Plans Gain Momentum
    • Glenn Close Honorary Oscar Marks Career Milestone
    • San Francisco 49ers Cowboys Victory Stuns Dallas
    • Trump Nvidia Stock Holdings Draw Fresh Scrutiny
    • Trump Faces Republican Resistance Over Judicial Appointments
    • Kayla Harrison Defeats Amanda Nunes to Retain UFC Title
    • US Mineral Supply Chain Still Depends Heavily on China
    • Democrats and Republicans Compete for Young Male Voters
    Mir NewsMir News
    • General
    • World
    • Finance
    • Money
    • Lifestyle
    • More
      • Culture
      • Travel & Tourism
      • Environment & Sustainability
    Subscribe
    • Latest News
    • Politics
    • Opinion
    • Business
    • Technology
    • Sports
    • Health
    • Education
    • Entertainment
    Mir NewsMir News
    Home » FDA Rejects Moderna’s mRNA Flu Vaccine, Delaying Approval
    Health

    FDA Rejects Moderna’s mRNA Flu Vaccine, Delaying Approval

    Mir NewsBy Mir NewsFebruary 11, 2026 10:30 am4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Agency Refuses to Review Seasonal Flu Shot

    The US Food and Drug Administration refused to accept Moderna’s application to review its first mRNA seasonal flu vaccine. The company announced the decision on Tuesday. The refusal marks another significant setback for mRNA vaccine development in the United States. Several officials in the Trump administration have recently criticized the technology.

    The FDA said the application lacked an adequate and well-controlled trial. The agency said the control group did not reflect the best available standard of care in the United States during the study. Moderna said regulators did not raise any safety or efficacy concerns.

    Moderna Disputes FDA Decision and Seeks Guidance

    Moderna said the refusal contradicted earlier feedback from the FDA. The company requested a meeting with regulators to clarify next steps.

    Moderna President Dr. Stephen Hoge said the agency never indicated the trial design was inadequate. He said the company followed the clinical approach discussed with regulators.

    Rare Refuse-to-File Letter Raises Industry Alarm

    The US Department of Health and Human Services said the FDA generally does not comment on communications with individual sponsors. Analysts said refuse-to-file letters remain rare. A 2021 study found only 4% of nearly 2,500 applications received such letters.

    Large Trial Compared Candidate Vaccine With Standard Flu Shot

    Moderna used the standard-dose flu vaccine Fluarix as a comparator in a trial involving 40,700 participants. The company said the FDA approved this plan in April 2024. Regulators suggested adding data comparing the vaccine with a high-dose flu shot for older adults. Moderna said it included that data.

    FDA Guidance Shifted Before Submission

    Moderna said the FDA suggested in August that it would review the filing and address comparator concerns during the process. The agency warned the data could pose a significant issue during review.

    The FDA later refused to conduct the review. Dr. Vinay Prasad signed the letter. He directs the FDA’s Center for Biologics Evaluation and Research, which oversees vaccine regulation.

    Leadership Record Fuels Controversy

    Prasad criticized the government’s Covid-19 response before joining the FDA under Health Secretary Robert F. Kennedy Jr. He claimed last year that Covid-19 vaccines caused deaths in 10 children without providing details. He said the agency will change its vaccine approval process.

    Policy Shifts Challenge mRNA Vaccine Developers

    Moderna is one of three approved Covid-19 vaccine manufacturers in the United States. Pfizer and Novavax are the other companies. Moderna and Pfizer use mRNA technology in their vaccines. Pfizer also develops mRNA-based flu vaccines.

    The first Trump administration supported rapid mRNA vaccine development during the pandemic. The second administration withdrew support for mRNA research in infectious diseases. The Department of Health and Human Services canceled 22 mRNA vaccine projects worth about $500 million in August. Officials claimed these vaccines do not protect effectively against upper respiratory infections like Covid-19 and flu.

    Scientists Highlight Promise of mRNA Vaccines

    Experts estimate Covid-19 vaccines saved millions of lives. Researchers hope mRNA technology can improve seasonal flu vaccines. Scientists believe the platform can enable regional tailoring and combination shots for flu and Covid-19.

    With current methods, experts select flu strains for seasonal vaccines in February. Hoge said mRNA vaccines can be manufactured much faster. He said Covid-19 vaccine designs were decided in May or June and shipped by August.

    Choosing strains closer to flu season could improve matching with circulating viruses. Better matching usually means better protection, Hoge said.

    Phase 3 Trial Shows Higher Efficacy

    Moderna’s phase 3 study showed the mRNA flu shot delivered about 27% higher efficacy than Fluarix in adults aged 50 and older. A separate trial comparing the vaccine with a high-dose flu shot for people aged 65 and older showed superior results, Moderna said.

    Scientists assess immune response by analyzing blood samples from vaccinated participants. Researchers assess efficacy by measuring protection against confirmed disease cases.

    Combination Flu and Covid-19 Vaccine Paused in the US

    Moderna planned to submit its combined flu and Covid-19 mRNA vaccine after the flu vaccine review began. The company paused that plan while awaiting further guidance from the FDA.

    The combination vaccine continues to move forward in other countries.

    “We expect our first approval probably in Europe this year,” Hoge said. “That will be a milestone event.”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleTraditional Nepalese Diet May Help Reverse Rising Diabetes Rates
    Next Article Devastating School Shooting Rocks Tumbler Ridge, B.C.
    Mir News
    • Website

    Related Posts

    New York Medicaid Fraud Probe Targets Care Sites

    October 21, 2026 10:46 am

    Quartz Countertop Health Hazards Danger Workers

    August 15, 2026 4:11 am

    Child Mental Health Crisis Grows Fast

    June 29, 2026 6:25 am
    Add A Comment
    Leave A Reply Cancel Reply

    Latest News

    Democrats and Republicans Compete for Young Male Voters

    November 15, 2026 3:31 pm

    New Orleans Boat Crash Leaves All 197 Passengers Safe

    November 14, 2026 6:18 am

    Central European University Plans Budapest Expansion

    November 14, 2026 5:44 am

    US Indicts Three Over Alleged Terror Plot at British Air Base

    November 13, 2026 11:09 am

    World Bank Establishes Doha Presence to Expand Regional Development Efforts

    Business January 26, 2026 12:17 am

    The World Bank Group has opened its first office in Doha, marking a new chapter…

    OpenAI AI Safety Pause Expands

    September 27, 2026 4:08 am

    Polar Bear DNA Changes May Help Species Cope With Warming Climate

    December 13, 2025 2:11 pm

    Maresca slams Delap’s ‘stupid red card’ as Chelsea survive wild Wolves fightback

    October 31, 2025 3:19 pm

    Mir News brings you fresh stories, news, culture, and trends from the United States and beyond — your daily source for insight, inspiration, and authentic perspectives.

    We're social. Connect with us:

    Facebook Instagram
    Categories
    • Business
    • Culture
    • Education
    • Entertainment
    • Environment & Sustainability
    • Health
    • Media
    • Latest News
    • Opinion
    • Real Estate
    • Sports
    • Technology
    • Travel & Tourism
    Latest News

    San Francisco 49ers Cowboys Victory Stuns Dallas

    November 16, 2026 2:32 pm

    Trump Nvidia Stock Holdings Draw Fresh Scrutiny

    November 16, 2026 2:29 pm

    US Mineral Supply Chain Still Depends Heavily on China

    November 15, 2026 3:37 pm
    All Rights Reserved © 2026 Mirnews.
    • Contact Us
    • Privacy Policy
    • Editorial Standards
    • Terms & Conditions
    • Disclaimer
    • Imprint

    Type above and press Enter to search. Press Esc to cancel.